30
total announcements
ORCHPHARMA.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹4,532 Cr
P/E (TTM)
555.0
P/E (Forward)
21.3
EPS (TTM)
₹1.61
52W Low
₹480.00
52W High
₹1,143.50
Dividend Yield
0.00%
Beta
0.49
Price / Book
3.5
Debt / Equity
28.2
Revenue (TTM)
₹852 Cr
Gross Margin
35.85%
Operating Margin
1.00%
Orchid Pharma Limited
Orchid Pharma Limited has informed the Exchange regarding allotment of 44,586,052 securities pursuant to Scheme of Arrangement/Amalgamation at its meeting held on August 01, 2026.
Orchid Pharma Limited
Orchid Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on August 01, 2026. The Board of Directors approved the issuance and allotment of 4,45,86,052 fully paid up equity shares of Rs. 10 each to the eligible shareholders of Dhanuka Laboratories Limited as on record date July 23, 2026, pursuant to the scheme of Amalgamation.
Orchid Pharma Limited
Orchid Pharma Limited has informed the Exchange regarding 'Intimation regarding investor roadshow ' to be held in Singapore on July 29-31, 2026.
Orchid Pharma Limited
Orchid Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the compliances required under the above said regulation.
Orchid Pharma Limited
Orchid Pharma Limited has informed the Exchange that the Record date for the purpose of Merger/HiveOff is 23-Jul-2026.
Orchid Pharma Limited
Orchid Pharma Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company, including the effectiveness of the Scheme, alteration of capital clause, fixing of record date, and share exchange ratio.
Orchid Pharma Limited
Orchid Pharma Limited has announced the outcome of its board meeting, noting the effectiveness of the scheme of amalgamation with Dhanuka Laboratories Limited, effective July 10, 2026. The company's authorized share capital has increased, and the record date for determining shareholders eligible for shares in the amalgamated company has been set as July 23, 2026.
Orchid Pharma Limited
Orchid Pharma Limited has informed the Exchange regarding the Scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited and their respective shareholders and creditors under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Orchid Pharma Limited
Orchid Pharma Limited has entered into a licensing and supply agreement with Pharmasyntez JSC, Russia, for the commercialization of Exblifep (Cefepime/Enmetazobactam) in Russia, a novel combination antibiotic for the treatment of complicated urinary tract infections and hospital-acquired and ventilator-associated bacterial pneumonia.
Orchid Pharma Limited
Orchid Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.